André Choulika

André Choulika (born 1965) is a biotechnologist, the inventor of nuclease-based genome editing and a pioneer in the analysis and use of meganucleases to modify complex genomes.

Early life and education André Choulika was born 1965 in Beirut, Lebanon to a Russian father and a Lebanese mother. He left Lebanon in 1982, arriving in France via Nicosia, Cyprus.

After attending school in Nice, he went on to study biology and virology at Pierre and Marie Curie University (Paris VI),

After receiving his doctorate in molecular virology from Pierre and Marie Curie University-Paris VI, André completed a postdoctoral fellowship with Richard C. Mulligan at Harvard Medical School in the Department of Genetics. This work represented the first use of chimeric nucleases to edit genomes by homologous recombination. Later, while working in the Division of Molecular Medicine at Boston Children's Hospital, he developed the first approaches to meganuclease-based human gene therapy.

Innovation and entrepreneurship In 1999, Choulika founded the biopharmaceutical company Cellectis as a spin-off from the Pasteur Institute. The Pasteur Institute transferred licensing rights on nine patent families, including several based on his own research. Cellectis' work is focused on developing immunotherapies to target and eradicate cancers. These are based on custom engineered CAR-T-cells (UCART), whose properties can be determined by genetic modification. The company's mission is to develop a new generation of cancer therapies based on these engineered T-cells. Choulika has been a strong proponent of gene editing technologies as a concept that would survive the 21st century.

In 2014, Cellectis entered into 2 strategic partnerships with Pfizer and Servier for collaboration on their cancer immunotherapy products. In 2018, Allogene assumed the global strategic partnership from Pfizer that was originally agreed upon in 2014. Both Servier and Allogene continue to work on UCART19 in patients with acute lymphoblastic leukemia (ALL).

Cellectis also has research alliances with a number of hospitals for their UCART clinical trials – among the first being Weill Cornell Medical College and the MD Anderson Cancer Center at the University of Texas.

An agricultural biotechnology subsidiary, Calyxt, Inc. (formerly Cellectis Plant Sciences, Inc.), was founded in 2010.

Awards and recognition

1999: Cellectis wins the Emerging Business category in a national competition for the creation of innovative technology companies, launched by Claude Allegre 2015: Cellectis named Company of the Year, European MedScience Awards 2016: Cellectis wins Most Innovative European Biotech SME in Healthcare, EuropaBio Awards 2016: Cellectis named as one of MIT Technology Review's 50 Smartest Companies

Personal life André Choulika has three children. LagoZ and LagZ, two genes derived from the LacZ gene to study epigenetics. I-SceI-induced gene replacement at a natural locus in embryonic stem cells. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae.

Selected patents